Navigation Links
TGen and Scottsdale Healthcare researchers discover microRNA role in brain metastasis
Date:4/1/2011

PHOENIX, Ariz. March 31, 2011 Conducting genetic profiles using microRNA can help doctors predict which lung cancer patients are likely to also develop brain metastasis (BM), according to a study published today by Scottsdale Healthcare and the Translational Genomics Research Institute (TGen).

The study identified microRNA-328 as a potential therapeutic target because of its association with the spread of cancer to the brain in patients with non-small cell lung cancer (NSCLC). NSCLC makes up 88 percent of the 222,000 annual U.S. cases of lung cancer, which is by far the most common of all cancers among Americans.

"This is one of the first studies using microRNA to identify lung cancer patients at risk for developing or likely to have brain metastasis," said Dr. Glen Weiss, the paper's senior author and Director of Thoracic Oncology at TGen Clinical Research Services at Scottsdale Healthcare. TCRS is a partnership between TGen and Scottsdale Healthcare that helps bring new therapies quickly to patients at the Virginia G. Piper Cancer Center in Scottsdale.

The paper, MicroRNA-328 is associated with non-small cell lung cancer (NSCLC) brain metastasis and mediates NSCLC migration, was published online today (March 31, 2011) by the International Journal of Cancer.

MicroRNAs are single-stranded RNA molecules that regulate how genes and proteins control cellular development. Because microRNAs are so resilient, they are relatively easy to detect in tumor tissue and blood, which is often a limitation for other biomarkers. In addition, one microRNA can regulate hundreds of genes.

"Previous efforts to characterize patients that will develop brain metastasis have been fairly disappointing," said Dr. Weiss. BM can cause neurologic, cognitive and emotional difficulties. "The ability to identify patients at risk for developing brain metastasis may lead to new prophylactic intervention that may mitigate morbidity and mortality."

Brain metastasis can cause severe side effects. Currently, brain metastasis is often identified on imaging scans when a lung cancer patient develops unexplained neurological symptoms. Then treatment often includes either surgery and/or radiation. There are no measures in place today to minimize risk. By using microRNA-328 as a biomarker, physicians might one day be able to identify patients most likely to benefit from earlier treatments such as prophylactic cranial irradiation, a strategy used in another type of lung cancer called small cell lung cancer.

The study used tumor specimens from Scottsdale Healthcare and University of Iowa Hospitals and Clinics. Over-expression of microRNA-328 resulted in an increase in cancer cell migration, the study said.

"The elevated expression of microRNA-328 in both thoracic and brain NSCLC samples suggests this microRNA may be involved in 'brain-seeking' metastatic potential," said Dr. Shilpi Arora, staff scientist at TGen and the paper's first author.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology technology :

1. MedTrust Online and Scottsdale Clinical Research Institute at Scottsdale Healthcare Announce Collaboration to Provide Cutting Edge Technology to Improve Patient Care
2. Lexicon Pharmaceuticals to Present at the 10th Annual Needham Healthcare Conference
3. Sangamo BioSciences Announces Presentation at the 10th Annual Needham Healthcare Conference
4. VIVUS to Present at the 10th Annual Needham Healthcare Conference
5. DRIVE4COPD Wins PRWeek Healthcare Campaign of the Year 2011
6. MiMedx Group, Inc. to Present at the 10th Annual Needham Healthcare Conference
7. Amgen to Present at the Cowen and Company 31st Annual Healthcare Conference
8. Savient Pharmaceuticals to Present at the Citi 2011 Global Healthcare Conference
9. Sensus Healthcare Announces Its Exhibitor Attendance at the 9th Annual South Beach Symposium™
10. Sensus Healthcare Announces the Formation of a Medical Advisory Board
11. Shionogi-ViiV Healthcare Starts Phase III Trial for 572-Trii Fixed-Dose Combination HIV Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2020)... ... August 13, 2020 , ... Inc. magazine today revealed that ... ranking of the nation’s fastest-growing private companies. The list represents a unique look ... small businesses. Intuit, Zappos, Under Armour, Microsoft, Patagonia, and many other well-known names ...
(Date:8/3/2020)... PHILADELPHIA (PRWEB) , ... August 03, 2020 , ... ... data collection, today announced Jim Corrigan, President and CEO has been named one ... a broad cross-section of industry sectors, PharmaVoice 100 honorees are selected based on ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... up to three different materials for use with CRM, neurostimulation, vascular, and related ... materials to meet specific design requirements, performance, and cost criteria; especially where solid ...
(Date:7/22/2020)... ... 22, 2020 , ... Join experts from Reed Tech , Gary Saner, ... a one hour live webinar on Thursday, August 13, 2020 at 11am ... and medical devices. Specifically, for medical devices, the NMPA has departments dealing with medical ...
Breaking Biology Technology:
(Date:8/7/2020)... ... August 06, 2020 , ... ... the prestigious National STEM Scholar Program, a unique professional development program that provides ... support for middle school science teachers nationwide. , Created in partnership between the ...
(Date:7/31/2020)... ... July 30, 2020 , ... BioFactura, Inc. today ... by the Joint Science & Technology Office—Chemical and Biological Defense (JSTO-CBD) of the ... and scale-up a highly efficient mammalian cell culture-based bioprocess suitable to meet surge ...
(Date:7/18/2020)... ... July 16, 2020 , ... ... effectiveness of the Invictus Medical Neoasis™ active noise control device to attenuate typical ... that the Neoasis™ device attenuated the alarm sounds from patient monitors, ventilators and ...
Breaking Biology News(10 mins):